证券代码：688310 证券简称：迈得医疗 迈得医疗工业设备股份有限公司 2025 年第二次临时股东会会议资料 二〇二五年十二月 1 | 2025 | 年第二次临时股东会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第二次临时股东会会议议程 | 6 | | 2025 | 年第二次临时股东会会议议案 | 8 | | | 议案一：关于以集中竞价交易方式回购公司股份方案的议案 | 8 | 二、为保证本次会议的严肃性和正常秩序，切实维护股东的合法权益，出席 会议的股东或其代理人须在会议召开前 30 分钟到会议现场办理签到手续，并请 按股东会登记方法等有关规定出示股东账户卡（如有）、身份证明文件或法人单 位证明、授权委托书等。在会议主持人宣布现场出席会议的股东和代理人人数及 所持有表决权的股份总数之前，会议登记应当终止。现场参会登记终止后出席的 股东或其代理人，不得参加现场表决，但可以列席会议。 三、会议按照会议通知上所列顺序审议、表决议案。 四、股东及股东代理人参加股东会依法享有发言权、质询权、表决权等权利。 股东及股东代理人参加股东会应认真履行其法定义务，不得侵犯公司和其他股东 ...

截至2025年12月18日收盘，迈得医疗（688310）报收于14.78元，较前一交易日上涨0.48%，最新总市值 为24.57亿元。该股当日开盘14.77元，最高15.05元，最低14.65元，成交额达4234.62万元，换手率为 1.71%。 公司近日发布公告，披露了关于回购股份事项前十大股东和前十大无限售条件股东的持股情况。公告显 示，迈得医疗工业设备股份有限公司于2025年12月11日召开第五届董事会第八次会议，审议通过以集中 竞价交易方式回购公司股份的议案。本公告披露了董事会公告回购股份决议前一个交易日（2025年12月 12日）登记在册的前十大股东及前十大无限售条件股东的持股情况，包括股东名称、持股数量和持股比 例。公司前两大股东分别为林军华和陈万顺，持股比例分别为47.15%和14.89%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《迈得医疗工业设备股份有限公司关于回购股份事项前十大股东和前十大无限售条件股东持股情 况的公告》 最新公告列表 ...

Core Viewpoint - The stock of Maide Medical (688310) has shown a slight increase, with a closing price of 14.78 yuan on December 18, 2025, reflecting a 0.48% rise, amidst mixed capital flows from different investor types [1]. Group 1: Stock Performance and Capital Flow - On December 18, 2025, Maide Medical's stock recorded a trading volume of 28,400 hands and a total transaction amount of 42.35 million yuan [1]. - The net inflow of main funds was 194,600 yuan, accounting for 0.46% of the total transaction amount, while retail investors saw a net inflow of 469,700 yuan, representing 1.11% [1]. - Over the past five days, the stock has experienced fluctuations in capital flow, with notable net inflows and outflows from different investor categories [2]. Group 2: Financial Metrics and Industry Comparison - Maide Medical's total market value is 2.457 billion yuan, significantly lower than the industry average of 7.693 billion yuan, ranking 227 out of 270 in the specialized equipment industry [3]. - The company reported a net profit of 8.8367 million yuan for the first three quarters of 2025, which is a 15.82% increase year-on-year, while its main revenue reached 225 million yuan, up 2.31% year-on-year [3]. - The gross profit margin stands at 40.19%, which is higher than the industry average of 27.79%, but the net profit margin is negative at -2.43%, significantly below the industry average of 4.37% [3].

Group 1 - Company announced a share repurchase plan to be approved at the board meeting on December 11, 2025 [1] - The top ten unrestricted shareholders hold approximately 119 million shares, accounting for 71.29% of total shares [1] - The largest shareholder, Lin Junhua, holds about 78.37 million shares, representing 47.15% [1] Group 2 - For the year 2024, the company's revenue composition shows that specialized equipment manufacturing accounts for 98.7% of total revenue, while other businesses account for 1.3% [2] - The current market capitalization of the company is 2.5 billion yuan [3]

证券代码：688310 证券简称：迈得医疗 公告编号：2025-053 一、公司前十大股东持股情况 | 7 | 张鹏 | 1,189,804 | 0.72 | | --- | --- | --- | --- | | 8 | 涂筱莲 | 1,029,682 | 0.62 | | 9 | 张海 | 1,018,202 | 0.61 | | 10 | 中国建设银行股份有限公司－交银施罗德稳 | 963,771 | 0.58 | | | 健配置混合型证券投资基金 | | | 二、公司前十大无限售条件股东持股情况 | 序号 | 持有人名称 | 持股数量 | 占总股本比例 | | --- | --- | --- | --- | | | | （股） | （%） | | 1 | 林军华 | 78,372,560 | 47.15 | | 2 | 陈万顺 | 24,754,800 | 14.89 | | 3 | 台州赛纳投资咨询合伙企业（有限合伙） | 5,727,120 | 3.45 | | 4 | 迈得医疗工业设备股份有限公司回购专用证 | 2,592,575 | 1.56 | | | 券账户 | | | | 5 | 申万菱 ...

Core Viewpoint - The company, Maide Medical, has announced a share repurchase plan approved by its board of directors during a meeting held on December 11, 2025, indicating a strategic move to enhance shareholder value [2]. Group 1 - The board of directors approved the proposal for share repurchase through centralized bidding [2]. - The details of the share repurchase plan were disclosed in a public announcement on December 13, 2025, on the Shanghai Stock Exchange [2]. - The announcement includes the resolution from the eighth meeting of the fifth board of directors [2].

Group 1 - The company is currently operating normally and has confirmed its business status in response to investor inquiries [1] - The commercialization of the company's contact lens business is still in its early stages, and its revenue has not yet significantly impacted overall company performance [1] - The company is in the process of applying for registration certificates for daily disposable soft hydrophilic contact lenses [1]

有投资者在投资者互动平台向 迈得医疗公司提问：1.贵公司近期下跌幅度远高于行业平均水平，是否经 营正常？2.隐形眼镜，上市后销售情况如何？3.日抛取证，预计什么时候有结论？ 迈得医疗回复称，公 司目前处于正常经营状态。公司隐形眼镜业务商业化尚处于起步阶段，收入对公司业绩尚未产生重大影 响。且公司目前正在申请佩戴周期为日抛的软性亲水接触镜注册证照。 ...

Group 1: Company Announcements - Yongding Co., Ltd. does not directly manufacture controllable nuclear fusion devices but provides materials for the winding magnets of such devices [1] - Aerospace Power's main business does not involve commercial aerospace, nor does it have any commercial aerospace-related assets for external investment [1] - Zhibang Home intends to repurchase company shares worth between 80 million to 110 million yuan [3] Group 2: Investment Projects - Jiangsu Longsheng Weirui plans to invest approximately 350 million yuan to establish an intelligent robot innovation center [1] - Hainan Development's Zhuhai Sanxin plans to invest in the second phase of its production base project in Zhuhai [2] - New Fengming intends to invest 280 million USD to build a 360,000 tons/year functional fiber project in Egypt [2] Group 3: Contracts and Bids - Dayu Irrigation has pre-won the construction project for high-standard farmland in Inner Mongolia's Chifeng City for 2025 [1] - Dayu Irrigation has also pre-won the construction project for high-standard farmland in Inner Mongolia's Tongliao City for 2025 [2] - *ST Zhisheng has won the bid for the smart city governance (Phase IV) project [1] Group 4: Equity Transactions - Rongzi Technology plans to acquire 54.9688% of Guizhou Xinren's shares for 342 million yuan and will also increase its capital [3] - Tiankang Biological intends to purchase 51% equity of Qiangdu Livestock [2] - Binhai Energy plans to acquire 51% equity of Xingtai New Energy [3] Group 5: Share Buybacks and Holdings - Maide Medical plans to spend between 20 million to 40 million yuan to repurchase shares [3] - Tianli Technology's Qian Yongyao intends to reduce his holdings by no more than 3% [3] - Haichuan Intelligent's Wu Guifang and Zheng Xuefen plan to collectively reduce their holdings by no more than 5.98% [3] Group 6: Fundraising Activities - Tianshun Wind Power plans to raise no more than 1.95 billion yuan through a private placement [3] - Leisai Intelligent plans to raise no more than 1.144 billion yuan through a private placement [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688310 证券简称：迈得医疗 公告编号：2025-051 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币2,000万元（含），不超过人民币4,000万元（含） ● 回购股份资金来源：公司首次公开发行股票超募资金或自有资金 ● 回购股份用途：用于减少公司注册资本 ● 回购股份价格：不超过人民币24元/股（含）。该价格不高于公司董事会通过回购股份决议前30个交 易日公司股票交易均价的150% ● 回购股份方式：集中竞价交易方式 ● 回购股份期限：自公司股东会审议通过本次回购股份方案之日起12个月内 ● 相关股东是否存在减持计划：公司董事、高级管理人员、控股股东、实际控制人及其一致行动人、回 购提议人、持股5%以上股东在未来3个月、未来6个月暂无减持公司股份的计划。若上述人员未来拟实 施股份减持计划，公司将按相关规定及时履行信息披露义务 本次回购股份方案尚需提交公司股东会审议。公司将于2025年12月30日召开2025 ...